Atlas Trials

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

Clinical trial NCT05026996 · COMPLETED

Trial details

NCT number
NCT05026996
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Hepatic Impairment
Start date
2021-11-23
Primary completion
2022-10-19
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.